Ophthalmic Drug articles & resources on Made-in-China.com

BioTime Has Entered Into a Sublicense Agreement with Jade Therapeutics

Sep 20, 2013

US-based biotechnology firm BioTime has entered into a sublicense agreement with Jade Therapeutics, a developer of ophthalmic sustained-release drug delivery platforms, for ophthalmic drug delivery applications of BioTime's HyStem ...

Tags: Health, Medicine, biotechnology

Insite Vision Secured The New Patent for Enhancing Drug Delivery System

Aug 20, 2013

InSite Vision has secured the new patent for its DuraSite 2 next-generation enhanced drug delivery system from the United States Patent and Trademark Office (USPTO). DuraSite 2's ability to significantly improve drug retention and ...

Tags: Insite Vision, Ophthalmic Drug

Healthcare Industry's Major Players Will Convene at The 12th Edition of Pharmapack Europe

Feb 6, 2013

On Feb. 13-14, 2013, the healthcare industry's major players will convene at the 12th edition of Pharmapack Europe at Grande Halle de la Villette (Paris). More than 3,000 visitors from four continents and more than 290 international ...

Tags: Pharmaceutical Packaging, Packaging Experts, Key Issues

InSite Launches a New Durasite 2 Drug Delivery System, Designed to Ophthalmic Therapeutics

Dec 14, 2012

InSite Vision has launched a new DuraSite 2 drug delivery system, designed to deliver ophthalmic therapeutics. DuraSite 2, which is based on InSite DuraSite technology, incorporates cataract surgery drug, ketorolac, a non-steroidal ...

Tags: InSite, Ophthalmic Drug Delivery System, ophthalmic therapeutics

Ophthalmic Drug

BioTime Has Entered Into a Sublicense Agreement with Jade Therapeutics

Insite Vision Secured The New Patent for Enhancing Drug Delivery System

Healthcare Industry's Major Players Will Convene at The 12th Edition of Pharmapack Europe

InSite Launches a New Durasite 2 Drug Delivery System, Designed to Ophthalmic Therapeutics

Related Products